A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
TGF-β1 type II receptor (TGF-βRII) expression in pulmonary arteries of patients with severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 96s Year: 2005
C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
Impact of blockers of AT1 receptors to angiotensin II on endothelium vasoregulating function in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19 Source: Eur Respir J, 57 (2) 2002737; 10.1183/13993003.02737-2020 Year: 2021
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Imbalanced expression of the type I TGF-beta receptors ALK-1 in pulmonary fibrosis Source: Annual Congress 2009 - Mechanisms of pulmonary inflammation and fibrosis Year: 2009
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011
The role of the accessory type III transforming growth factor-β receptors in the regulation of pulmonary vascular development Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011
Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007
Effects of type I, II and III interferons on endothelin-1 release by human pulmonary artery smooth muscle cells Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011
Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012
Refractory remodeling of intrapulmonary arteries by type V collagen, apoptosis and endothelial activation in experimental systemic sclerosis Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Sildenafil modulates PDGF and Angiotensin II induced migration and proliferation in human pulmonary artery smooth muscle cells (PA-SMC) Source: Eur Respir J 2002; 20: Suppl. 38, 227s Year: 2002
Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery Source: Eur Respir J 2001; 18: 5-14 Year: 2001
Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002
Increased angiotensin II (Ang II) and oxidants are critical for angiogenesis and endothelial receptor for oxidized LDL (LOX-1) expression in obstructive sleep apnea (OSA) patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Angiotensin II and hypoxia synergistically induce proliferation in pulmonary artery fibroblasts by a PI-3K and PKC-signaling pathway through HIF-1 a and upregulation of angiotensin II-receptors type I Source: Eur Respir J 2002; 20: Suppl. 38, 378s Year: 2002
Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010